Komori
Human Metabolome Technologies (6090) · TargetWorsened

Numerical Targets in the Medium-Term Management Plan Through the Fiscal Year Ending June 2026

First written in FY2021. 5 of 7 entries say "Worsened", first in FY2024. Latest entry: FY2026.

7entries
6years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021RaisedFY2023WorsenedFY2024 – FY20262021: 120212022: 020222023: 120232024: 120242025: 020252026: 42026
Same theme, other companies
Setting and Achieving Earnings Targets Under the Medium-Term Management PlanA theme 786 companies write about · 73 as a headwind · 1057 as a tailwind

The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 133 companies compared. The sentences above are computed from all 133.Comparing 200 of the theme's 1175 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「Meanwhile, the life science research support services business recorded lower revenue for the third consecutive year and was the main reason the Group as a whole fell short of the medium-term management plan.」

    The Company stated that, under the medium-term management plan through the fiscal year ending June 2026, the life science research support services business’s three consecutive years of revenue declines were the main reason the overall plan targets were not achieved.
  2. FY2024WorsenedAnnual report

    「The Group achieved its 11th consecutive year of revenue growth during the current consolidated fiscal year. Operating income also increased 4.4% year on year, but fell short of the targets of the medium-term management plan.」

    The Company continues to target consolidated net sales of ¥1.6 billion and consolidated operating income of ¥300 million for the fiscal year ending June 2026, but disclosed that it had fallen short of the medium-term management plan targets as of the current consolidated fiscal year.
  3. FY2023RaisedAnnual report

    「Under the medium-term management plan through the fiscal year ending June 2026 disclosed in August 2023, the Company has set the following management targets for the final year as milestones on the way to realizing its corporate philosophy: 1) Consolidated net sales: ¥1.65 billion 2) Consolidated operating income: ¥300 million」

    The Company updated its targets and levels from the previous targets for the fiscal year ending June 2026 of consolidated net sales of ¥1.6 billion and net income of ¥200 million to consolidated net sales of ¥1.65 billion and consolidated operating income of ¥300 million.
  4. FY2021First statedAnnual report

    「1) Consolidated net sales: ¥1.6 billion (average annual growth rate of 7% or more over 5 years) 2) Net income attributable to owners of the parent: ¥200 million 3) Financial position: transition to a financial position capable of paying dividends」

    For the 5-year medium-term management plan ending with the fiscal year ending June 2026, the Company disclosed for the first time its targets of consolidated net sales of ¥1.6 billion, an average annual growth rate of at least 7%, net income attributable to owners of the parent of ¥200 million, and a transition to a financial position capable of paying dividends.
Moved together

"Further Penetration of Overseas Markets and Winning Orders in Asia" moved the same way as this thread, in the same document, in 5 of its 7 moves.

554442★123456
  1. ★This thread
  2. 1Further Penetration of Overseas Markets and Winning Orders in Asia5×
  3. 2Growth and Improved Profitability of the Metabolome Analysis Business5×
  4. 3Improvement in profitability of the metabolome analysis business4×
  5. 4Sustainable revenue growth in the Advanced Research and Development Support Business and the early establishment of the Healthcare Solutions Business4×
  6. 5Timing Shift in Large-Scale Project Orders and Sluggish Execution of Customer Budgets4×
  7. 6Proactive Promotional Activities and Acquisition of Large-Scale Projects2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet. It last moved in the Earnings presentation of 2026-08-20: "Worsened".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Numerical Targets in the Medium-Term Management Plan Through the Fiscal Year Ending June 2026 | Human Metabolome Technologies,Inc. (6090) | Komori